Application of APT1 inhibitors in the preparation of drugs to enhance the sensitivity of Cxcl9-low-expressing tumors to combination therapy
By using APT1 inhibitors to enhance the sensitivity of combination therapy to tumors with low Cxcl9 expression, the problem of insensitivity in some patients to combination therapy with PARP inhibitors and ICBs was solved, significantly improving treatment efficacy and patient survival.
Patent Information
- Application Number
- CN202611465345.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-20
- Publication Date
- 2026-11-10
AI Technical Summary
In current combination therapy of PARP inhibitors and ICBs, some patients are not sensitive to the combination therapy, resulting in ineffective tumor control and failing to meet the treatment needs of all cancer patients.
APT1 inhibitors, including knocking out or knocking down the gene encoding APT1 or reducing the expression or activity of APT1 protein, combined with PARP inhibitors and immune checkpoint inhibitors, are used to enhance the sensitivity of combination therapy to tumors with low Cxcl9 expression.
It significantly improves the response rate and treatment efficacy of combination therapy in patients with low Cxcl9 expression tumors, and improves their quality of life.
Smart Images

Figure CN123059162A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biomedical technology, specifically relating to the application of APT1 inhibitors in the preparation of drugs for enhancing the sensitivity of Cxcl9-low-expressing tumors to combination therapy. Background Technology
[0002] Cancer has become a major disease threatening the health and lives of Chinese residents. In recent years, its incidence rate has shown a significant upward trend. Among them, melanoma is a highly malignant tumor with a very poor prognosis for patients in the late stage, especially metastatic melanoma patients, whose disease progresses rapidly and whose quality of life deteriorates severely, making clinical treatment urgently needed. Currently, clinical treatments for tumors mainly include surgery, traditional radiotherapy and chemotherapy, and immunotherapy. Among these, treating cancer through the immune system is an effective method with fewer side effects. With the advent of immune checkpoint blockade (ICB), drugs targeting immune checkpoints such as programmed cell death protein 1 (PD-1) and its ligand PD-L1 have emerged, such as nivolumab and pembrolizumab. ICB therapy has become a hot research topic in cancer treatment. However, clinical results have shown that in a considerable number of patients, ICB therapy still suffers from poor efficacy and low response rates.
[0003] In recent years, an increasing number of studies have focused on combination therapies to improve the efficacy of immune checkpoint inhibitors. Research indicates that the combination therapy of poly(ADP-ribose) polymerase (PARP) inhibitors and immune checkpoint inhibitors (ICBs) can significantly inhibit tumor growth by regulating cytokine secretion. This combination therapy strategy has entered clinical trials. Results show that although some patients achieved partial or complete remission after treatment, many others were insensitive to this combination therapy, with their tumors not being effectively controlled or even experiencing continuous progression, leading to treatment failure and failing to meet the treatment needs of all cancer patients.
[0004] Therefore, improving the response rate of PARP inhibitors combined with ICBs and addressing the issue of treatment insensitivity in some patients have become key technological bottlenecks that urgently need to be overcome in the field of tumor immunotherapy. Summary of the Invention
[0005] The purpose of this invention is to provide a drug for enhancing the response rate and efficacy of combination therapy, thereby improving the response rate and efficacy of PARP inhibitors combined with ICBs and addressing the problem of treatment insensitivity in some patients.
[0006] This invention first provides the use of APT1 inhibitors in the preparation of medicaments for enhancing the sensitivity of Cxcl9-low-expressing tumors to combination therapy, wherein the combination therapy includes at least immunotherapy.
[0007] Preferably, the APT1 inhibitor comprises a substance that knocks out or knocks down the APT1 coding gene, or reduces the expression level or activity of the APT1 protein, or weakens the effect of APT1, wherein the substance comprises any one or more combinations of proteins, nucleic acid molecules, small molecule compounds, or gene intervention tools.
[0008] Preferably, the APT1 inhibitor comprises Palmostatin B or shRNA targeting ATP1, the shRNA comprising a sense strand and an antisense strand, the nucleotide sequence of the sense strand being as shown in SEQ ID NO: 1, and the nucleotide sequence of the antisense strand being as shown in SEQ ID NO: 2.
[0009] Another aspect of the present invention provides a pharmaceutical composition for combination therapy, the pharmaceutical composition comprising: an immune checkpoint inhibitor, a PARP inhibitor, and an APT1 inhibitor. The APT1 inhibitor comprises a substance that knocks out or knocks down the APT1 coding gene, or reduces the expression level or activity of the APT1 protein, or weakens the effect of APT1; the PARP inhibitor comprises a substance that knocks out or knocks down the PARP coding gene, or reduces the expression level or activity of the PARP protein, or weakens the effect of PARP; the substance comprises any one or more combinations of proteins, nucleic acid molecules, small molecule compounds, or gene intervention tools.
[0010] Preferably, the APT1 inhibitor comprises Palmostatin B or shRNA targeting ATP1, the shRNA comprising a sense strand and an antisense strand, the nucleotide sequence of the sense strand being as shown in SEQ ID NO: 1, and the nucleotide sequence of the antisense strand being as shown in SEQ ID NO: 2.
[0011] Preferably, the immune checkpoint inhibitor includes at least one of the following: anti-CTLA4 antibody, anti-PD-1 antibody, anti-LAG 3 antibody, anti-OX40 antibody, anti-TIM3 antibody, and anti-PD-L1 antibody.
[0012] Preferably, the PARP inhibitor includes BMN673.
[0013] In another aspect, the present invention provides the use of the aforementioned pharmaceutical composition in the preparation of a medicament for treating tumors with low Cxcl9 expression.
[0014] Preferably, the tumor includes melanoma.
[0015] Compared with the prior art, the beneficial effects of the present invention include at least the following: This invention is the first to discover that tumor patients with low Cxcl9 expression have very low sensitivity to the combined use of PARP inhibitors and ICBs. Further research revealed that Cxcl9 can alter the depalmitoylation process of PD-L1 (Programmed Death-Ligand 1) by affecting the expression or activity of APT1 (acylprotein thioesterase), thereby changing the membrane localization level of PD-L1 and affecting the efficacy of combination therapy.
[0016] Based on the above research findings, this invention designs and uses an APT1 inhibitor to reverse the changes in PD-L1 levels on the membrane caused by low Cxcl9 expression. Experiments have confirmed that the use of APT1 inhibitors can enhance the sensitivity of tumor patients with low Cxcl9 expression to the combined treatment of PARP inhibitors and ICBs, significantly improve the response rate and treatment effect of tumor patients with low Cxcl9 expression to the combined treatment, and improve patient survival. It has high clinical value and application prospects. Attached Figure Description
[0017] Figure 1 The results indicate the detection efficiency of Cxcl9 and APT1 knockdown in cells, where: 'a' indicates the efficiency of Cxcl9 knockdown in cells as detected by ELISA. b indicates the Cxcl9 knockdown efficiency of cells detected by qPCR experiment; c indicates that the knockdown efficiency of the APT1 gene in the Cxcl9 knockdown cell line was detected by Western blot experiment.
[0018] Figure 2 This indicates the effect of shAPT1 on combination therapy for tumors with low Cxcl9 expression, including: a represents the tumor volume proliferation curve of each group of mice; b represents the comparison of tumor weight among the mice in each group; c represents a photograph of the tumor tissue of each group of mice.
[0019] Figure 3 This indicates the effect of Palmostatin B on combination therapy for tumors with low Cxcl9 expression, including: a represents the tumor volume proliferation curve of each group of mice; b represents the comparison of tumor weight among the mice in each group; c represents a photograph of the tumor tissue of each group of mice. Detailed Implementation
[0020] The technical solution of the present invention will be further described below with reference to the accompanying drawings and embodiments.
[0021] As mentioned earlier, clinical trials have found that a significant number of patients still exhibit low sensitivity to the combination therapy of PARP inhibitors and ICBs, with tumors failing to be effectively controlled or even progressing after treatment. Therefore, there is an urgent need in this field to improve the response rate of PARP inhibitor-ICB combination therapy and address the issue of treatment insensitivity in some patients.
[0022] To address the aforementioned issues, our research group conducted extensive studies and experiments. First, using CRISPR-screening technology, we identified Cxcl9 (CXC Chemokine Ligand 9) as a factor influencing the sensitivity of patients to the combined treatment of PARP inhibitors and ICBs. Specifically, tumor patients with low Cxcl9 expression showed lower sensitivity to the combined use of PARP inhibitors and ICBs; therefore, we considered enhancing the sensitivity of these patients to this combination therapy. Further research revealed that Cxcl9 can alter the depalmitoylation process of PD-L1 by affecting the expression or activity of APT1 (acylprotein thioesterase), thereby changing the membrane localization level of PD-L1 and influencing the efficacy of combination therapy. Specifically, patients with high Cxcl9 expression had higher PD-L1 membrane localization levels, while those with low expression had lower levels. Therefore, this invention designs the use of APT1 inhibitors to reverse the changes in PD-L1 levels on the membrane caused by low Cxcl9 expression, aiming to enhance the sensitivity of tumors with low Cxcl9 expression to combination therapy. Ultimately, experiments confirmed that the use of APT1 inhibitors can enhance the sensitivity of tumor patients with low Cxcl9 expression to the combined treatment of PARP inhibitors and ICBs, significantly improving the response rate and treatment efficacy of the combination therapy in patients with low Cxcl9 expression, thereby improving patient survival.
[0023] Based on the above, the present invention ultimately provides the use of APT1 inhibitors in the preparation of medicaments for enhancing the sensitivity of Cxcl9-low-expressing tumors to combination therapy, wherein the combination therapy includes at least immunotherapy.
[0024] The present invention also provides a pharmaceutical composition for combination therapy, the pharmaceutical composition comprising: an immune checkpoint inhibitor, a PARP inhibitor, and an APT1 inhibitor. The APT1 inhibitor comprises a substance that knocks out or knocks down the APT1 coding gene, or reduces the expression level or activity of the APT1 protein, or weakens the effect of APT1; the PARP inhibitor comprises a substance that knocks out or knocks down the PARP coding gene, or reduces the expression level or activity of the PARP protein, or weakens the effect of PARP; the substance comprises any one or more combinations of proteins (such as proteins, peptides), nucleic acid molecules (such as shRNA, microRNA, siRNA, and / or antisense oligonucleotides), small molecule compounds, or gene intervention tools.
[0025] In some embodiments, the APT1 inhibitor is Palmostatin B or a shRNA (small hairpin RNA) targeting ATP1, wherein the shRNA comprises a sense strand and an antisense strand, the nucleotide sequence of the sense strand being shown in SEQ ID NO: 1 and the nucleotide sequence of the antisense strand being shown in SEQ ID NO: 2.
[0026] In some embodiments, the immune checkpoint inhibitor includes at least one of anti-CTLA4 antibody, anti-PD-1 antibody, anti-LAG 3 antibody, anti-OX40 antibody, anti-TIM3 antibody, and anti-PD-L1 antibody.
[0027] The PARP (Poly(ADP-ribose) polymerase) gene family encodes poly(ADP-ribose) polymerases, a class of enzymes involved in various cellular processes such as DNA damage repair, gene expression regulation, and apoptosis. PARP1 and PARP2 are the most well-known members. As a specific example, the PARP inhibitor is BMN673. BMN673 (Talazoparib) is a highly effective orally active PARP1 / 2 inhibitor; in other embodiments, the PARP inhibitor may also be any one or a combination of olaparib, rucaparib, fuzolaparib, or pamiparib.
[0028] In some embodiments, the pharmaceutical composition further includes a pharmaceutically acceptable carrier. "Pharmaceutically acceptable carrier" refers to a carrier used for the administration of a therapeutic agent, including various excipients and diluents. This term refers to pharmaceutical carriers that are not essential active ingredients themselves and do not cause excessive toxicity after administration. Suitable pharmaceutically acceptable carriers are well known to those skilled in the art. A thorough description of pharmaceutically acceptable carriers can be found in Remington's Pharmaceutical Sciences. Pharmaceutically acceptable carriers in the composition may contain liquids such as water, phosphate buffer, Ringer's solution, physiological saline, balanced salt solution, glycerol, or sorbitol. Additionally, these carriers may contain auxiliary substances such as lubricants, flow aids, wetting agents or emulsifiers, pH buffers, and stabilizers such as albumin.
[0029] The present invention also provides the use of the aforementioned pharmaceutical composition in the preparation of a medicament for treating tumors with low Cxcl9 expression. In some embodiments, the tumor includes melanoma.
[0030] The experimental procedures and results of this invention are described in detail below. Unless otherwise specified, the reagents or materials used in the embodiments of this invention are commercially available products. The main reagents used include: Palmostatin B (MCE, catalog number 178501); BMN673 (Talazoparib) (Selleck, catalog number S7048); and anti-PD1 antibody (Bioxcell, catalog number BE0273).
[0031] Example 1: shAPT1 can enhance the sensitivity of tumors with low Cxcl9 expression to combination therapy with PARP inhibitors and ICBs. 1. Construction of Cxcl9 knockdown cell lines (1) Reagent preparation Preparation of LB liquid culture medium: Dissolve 2.5 g of LB broth powder in 100 mL of ultrapure water, shake thoroughly to mix, autoclave at 121℃, and store at 4℃ for later use.
[0032] Preparation of LB solid medium: Dissolve 3.2 g of LB agar powder in 100 mL of ultrapure water, mix thoroughly, and autoclave at 121 °C. Once the solution temperature has cooled to 55-60 °C, add 100 μL of ampicillin (10 mg / mL), shake to mix, and pour into sterile petri dishes, 10-20 mL per dish. After the medium has completely solidified, seal with sealing film and store at 4 °C for later use.
[0033] Preparation of 50×TAE buffer: Weigh 24.2 g of Tris base (2M) and 3.72 g of Na2EDTA·2H2O (0.1 M), add 80 mL of ultrapure water and stir until completely dissolved. Then add 5.71 mL of glacial acetic acid, mix well and bring the volume to 100 mL. Store at room temperature for later use.
[0034] (2) Design and construction of shCxcl9 plasmid 1) Plasmid design: The Cxcl9 gene sequence number was found on the NCBI website, and the shRNA, denoted as shCxcl9, was designed using Thermo Fisher's RNAiDesigner tool. This shRNA includes a forward sequence and a reverse sequence. The forward sequence of shCxcl9 is: CCGGAGCTGATGAAAGAATGGGAAAC TCGAGTTTCCCATTCTTTCATCAGCTTTTTTG (SEQ ID NO: 3); The reverse sequence of shCxcl9 is: AATTCAAAAAACCGGAGCTGATGAAAGAATGGGAAACTC GAGTTTCCCATTCTTTCATCAGC (SEQ ID NO: 4).
[0035] Upstream and downstream primers containing the forward and reverse sequences of shCxcl9 were synthesized based on the target vector sequence PLKO.1-puro (source: addgene website). The GC content of the primers was 52%-58%, and the Tm value was 64-66℃. Sequence comparison was performed using Snapgene.
[0036] The above sequence was synthesized by a biotechnology company, and the deliverable was a dry powder. The dry powder was prepared into a 20 μM stock solution and then stored in separate devices at -20°C for later use.
[0037] 2) Primer annealing and ligation: 5 μL of 10×NEB buffer, 10 μL of upstream and downstream primers, add water to 50 μL, anneal at 95℃ for 10 minutes, then slowly cool down in a gradient, collect the product, and obtain the insert fragment.
[0038] 3) Vector double digestion and PCR agarose gel recovery: After double digestion of the vector plasmid PLKO.1-puro (with both AgeI and EcoRI enzymes), the fragment was recovered by gel electrophoresis on a 2% agarose gel at a constant voltage of 20V, and the 7kb vector fragment was collected.
[0039] 4) Ligation of insert and vector fragments: The insert and vector fragments obtained above are mixed at a molar ratio of 20:1 and ligated overnight at 16°C using T4 ligase to obtain the ligation product, namely the shCxcl9 plasmid.
[0040] 5) Plasmid transformation: Thaw 100 μL of competent cells (DH5α E. coli) on ice, add 5 μL of ligation product (shCxcl9 plasmid), mix gently, place on ice for 30 minutes, heat shock at 42℃ for 45 seconds, then quickly incubate on ice for 2 minutes. Add 1 mL of LB liquid medium containing ampicillin for recovery culture (37℃, 1 h). Centrifuge and concentrate, then plate onto LB agar plates containing ampicillin and incubate upside down at 37℃ for 14 h. Pick single colonies, inoculate with LB liquid medium containing ampicillin for amplification, extract plasmid, and send for sequencing verification. After confirming the sequencing results are correct, further amplification and plasmid extraction are performed.
[0041] (3) Construction and infection of recombinant viral vectors 1) Virus preparation a. Preparation before transfection: 18-24 hours before the experiment, 293T cells were seeded in 10 cm culture dishes in complete DMEM medium containing 10% FBS (fetal bovine serum) and 1% penicillin and streptomycin. When the cell density reached 85%-90% confluence, the pre-warmed complete medium was replaced (to maintain serum and antibiotics). After 30 minutes of equilibration, the transfection operation was performed.
[0042] b. Transfection: Note that this step should be performed in a biosafety cabinet. Take a sterile 1.5 mL centrifuge tube, aspirate 500 μL of DMEM medium (without serum and antibiotics), add 5 ng of viral packaging plasmid (PS), 10 ng of envelope plasmid (PM), and 5 ng of target plasmid (shCxcl9 plasmid), and mix thoroughly by inverting to obtain a plasmid mixture. Take another sterile 1.5 mL centrifuge tube, aspirate 500 μL of DMEM medium (without serum and antibiotics), add 60 μL of transfection reagent PolyJet, and mix thoroughly by inverting to obtain a PolyJet dilution.
[0043] PolyJet dilution was then added to the plasmid mixture, gently vortexed to mix, and allowed to stand at room temperature for 10 minutes to form the PolyJet-plasmid complex. The PolyJet-plasmid complex was then evenly dropped into a culture dish seeded with 293T cells (in DMEM medium without serum and antibiotics), and cultured at 37°C, 5% CO2, and 95% humidity for 48 hours.
[0044] c. Virus Collection: After culture, aspirate the supernatant into a 15 mL centrifuge tube and centrifuge at 4000 rpm for 5 minutes to remove the bottom cell pellet to prevent filter clogging. Using a 10 mL disposable syringe, aspirate the supernatant, attach a 0.45 μm filter, and gently push the syringe to collect the resulting filtrate (virus suspension) into a new 15 mL sterile centrifuge tube. Then aliquot and store at -80°C for later use.
[0045] 2) Viral infection To determine the sensitivity threshold of B16F10 cells to puromycin, cells were sputtered at a concentration of 3 × 10⁻⁶ cells / year. 4 Cells were seeded at a density of 1 cell / well in 24-well culture plates. After confirming good cell status and confluence of 30% by microscopic observation, the following treatments were performed: the experimental groups were treated with complete DMEM medium containing 0.5 to 5 μg / mL (in 0.5 μg / mL gradients), while the control group was treated with complete DMEM medium without puromycin, with each well containing 1 mL. During culture, the medium was replaced with fresh medium every 48 hours, and cell viability was continuously observed; suspended cells were considered dead. After 6 days of culture, the results showed that the lowest effective concentration that caused complete cell death at the bottom of the culture plate was 1 μg / mL. Based on this result, 1 μg / mL will be used as the puromycin treatment concentration for cells in subsequent screening experiments.
[0046] Twenty-four hours before infection, melanoma cells (wild-type or stable B16F10 cell lines) were seeded into cell culture plates. On the day of infection, cell morphology was assessed and density was measured to ensure 20%-30% coverage. Then, the following steps were performed: In a UV-sterilized biosafety cabinet, the supernatant of the cell culture plate was removed, and 1 mL of complete DMEM medium, 1 mL of virus suspension, and 2 μL of polybrene (10 mg / mL) were added. The mixture was then horizontally vortexed and cultured for another 24 hours. The old medium was then removed, and 2 mL of fresh complete DMEM medium was added. Culture was continued for another 24 hours until day three, when microscopic observation confirmed good cell condition. Subsequently, 5 × 10⁶ cells were seeded into the culture plate. 5 The cell suspensions were seeded into culture containers (experimental group), and an equal number of wild-type cells were set up as a parallel control (control group). After culturing in complete DMEM medium for 24 hours, the old medium was removed, and complete DMEM medium containing 1 μg / mL puromycin was added for continued culturing.
[0047] During the 5-7 day culture period, cell morphology characteristics were monitored regularly, and the culture medium containing puromycin was replaced simultaneously to ensure the stability of the screening conditions. Once the wild-type cells in the control group were completely inactivated, the surviving virus-infected cells in the experimental group were confirmed as successfully transfected cell populations, i.e., the Cxcl9 knockdown cell line. Furthermore, this invention also constructed a non-knockdown Cxcl9 cell line (shCtrl) by transfecting an empty plasmid with a viral vector, which served as an experimental control.
[0048] Furthermore, the Cxcl9 knockdown efficiency of cells was detected by ELISA and qPCR experiments, respectively, and the results are as follows: Figure 1 As shown in Figures ab, these cells were able to stably express the shCxcl9 plasmid and significantly reduce the Cxcl9 expression level.
[0049] 2. Construct a stable APT1 knockdown cell line based on the Cxcl9 knockdown cell line. The Cxcl9 knockdown cell lines obtained above were then subjected to APT1 knockdown. The knockdown principle and operation procedure were the same as those for the Cxcl9 knockdown experiment. Those skilled in the art can refer to the above operation for relevant processing. Detailed explanations will not be provided here.
[0050] First, the shAPT1 plasmid (i.e., shRNA targeting APT1) was designed and constructed. The forward sequence of shAPT1 is: CCGGCCCTAATGTTTGGTTCTCTTACTCGAGTAA GAGAACCAAACATTAGGGTTTTTG (SEQ ID NO: 1); The reverse sequence of shAPT1 is: AATTCAAAAAACCCTAATGTTTGGTTCTCTTACTCGAGTAAGAGAA CCAAACATTAGGG (SEQ ID NO: 2).
[0051] The constructed shAPT1 plasmid was delivered into a Cxcl9 knockdown cell line via a viral vector. After screening and identification, a Cxcl9-APT1 double knockdown cell line was obtained. The knockdown efficiency of the APT1 gene in the Cxcl9 knockdown cell line was verified by Western blot experiments, and the results are as follows: Figure 1 As shown in c, compared with the control group (shCtrl), the APT1 expression level in the experimental group (shAPT1) cells was significantly reduced.
[0052] 3. Animal experiments Several 6-8 week old, approximately 20g weight, specific pathogen-free (SPF) female C57BL / 6 mice were selected and placed in a SPF-rated animal room with sufficient living space, food, and water. The number of mice per cage did not exceed 5. The mice were grouped and treated as shown in Table 1.
[0053] Table 1. Grouping and treatment of mice in Example 1 Starting on the seventh day after tumor injection, the long and short diameters of the tumors in each group of mice were measured every three days. The tumor volume was calculated as 1 / 2 × long diameter × short diameter × short diameter to obtain the tumor volume proliferation curve. On the 19th day, the mice were dislocated and died suddenly. The tumor tissue was dissected, weighed, and photographed.
[0054] The results are as follows Figure 2 As shown in the AC diagram, comparing the treatment effects between the shCtrl-lso group and the shCtrl-B+P group, and between the shCxcl9-lso group and the shCxcl9-B+P group, it was observed that compared to mice without Cxcl9 knockdown, Cxcl9 knockdown mice showed very low sensitivity to the combination therapy (PAPR inhibitor + ICB), and the treatment effect did not reach statistical significance. However, after ATP1 knockdown treatment, the tumor volume of Cxcl9 knockdown mice significantly decreased and the tumor weight was greatly reduced after combination therapy.
[0055] The above results indicate that inhibiting APT1 expression can effectively enhance the sensitivity of Cxcl9-low-expressing melanoma mice to combined treatment with PARP inhibitors and ICBs, thereby improving the efficacy of tumor treatment.
[0056] Example 2: Palmostatin B can enhance the sensitivity of tumors with low Cxcl9 expression to combined treatment with PARP inhibitors and ICBs. Palmostatin B is an acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitor. This example also evaluates the effect of Palmostatin B on combination therapy (PARP inhibitor in combination with ICB) for Cxcl9 low-expression tumors through animal experiments.
[0057] Several 6-8 week old, approximately 20g weight, specific pathogen-free (SPF) female C57BL / 6 mice were selected and placed in a SPF-rated animal room with sufficient living space, food, and water. The number of mice per cage did not exceed 5. The mice were grouped and treated as shown in Table 2.
[0058] Table 2. Mouse grouping and treatment in Example 2 Starting on the seventh day after tumor injection, the long and short diameters of the tumors in each group of mice were measured every three days. The tumor volume was calculated as 1 / 2 × long diameter × short diameter × short diameter to obtain the tumor volume proliferation curve. On the 22nd day, the mice were dislocated and died suddenly. The tumor tissue was dissected, weighed, and photographed.
[0059] The results are as follows Figure 3 As shown in the ac, Cxcl9 knockdown mice showed low sensitivity and poor efficacy to the combination therapy (PAPR inhibitor + ICB). However, mice treated with Palmostatin B and the combination therapy (PAPR inhibitor + ICB) showed significant reductions in tumor volume and size. This indicates that Palmostatin B can effectively enhance the sensitivity of Cxcl9-low expression melanoma mice to the combination therapy of PAPR inhibitor and ICB, resulting in a significant improvement in tumor treatment efficacy.
[0060] In summary, this invention provides the application of APT1 inhibitors in the preparation of drugs for enhancing the sensitivity of Cxcl9-low-expressing tumors to combination therapy. Experiments have demonstrated that the use of APT1 inhibitors can enhance the sensitivity of Cxcl9-low-expressing tumor patients to combination therapy with PARP inhibitors and ICBs, improving treatment outcomes and survival, thus possessing high clinical value and application prospects.
[0061] Although the present invention has been described in detail through the preferred embodiments above, it should be understood that the above description should not be considered as a limitation of the present invention. Various modifications and substitutions to the present invention will be apparent to those skilled in the art after reading the above description. Therefore, the scope of protection of the present invention should be defined by the appended claims.
Claims
1. The use of APT1 inhibitors in the preparation of drugs for enhancing the sensitivity of Cxcl9-low-expressing tumors to combination therapy, characterized in that, The combined treatment includes at least immunotherapy.
2. The application as described in claim 1, characterized in that, The APT1 inhibitors include substances that knock out or knock down the APT1 coding gene, or reduce the expression level or activity of the APT1 protein, or weaken the effect of APT1. The substances include any one or more combinations of proteins, nucleic acid molecules, small molecule compounds, or gene intervention tools.
3. The application as described in claim 1, characterized in that, The APT1 inhibitor includes Palmostatin B or an APT1-targeting shRNA, the shRNA comprising a sense strand and an antisense strand, the nucleotide sequence of the sense strand being shown in SEQ ID NO: 1, and the nucleotide sequence of the antisense strand being shown in SEQ ID NO:
2.
4. A pharmaceutical composition for combination therapy, characterized in that, The pharmaceutical composition includes: immune checkpoint inhibitors, PARP inhibitors, and APT1 inhibitors.
5. The pharmaceutical composition for combination therapy as described in claim 4, characterized in that, The APT1 inhibitor includes substances that knock out or knock down the APT1 coding gene, or reduce the expression level or activity of the APT1 protein, or weaken the effect of APT1; the PARP inhibitor includes substances that knock out or knock down the PARP coding gene, or reduce the expression level or activity of the PARP protein, or weaken the effect of PARP; the substances include any one or more combinations of proteins, nucleic acid molecules, small molecule compounds, or gene intervention tools.
6. The pharmaceutical composition for combination therapy as described in claim 4, characterized in that, The APT1 inhibitor includes Palmostatin B or an APT1-targeting shRNA, the shRNA comprising a sense strand and an antisense strand, the nucleotide sequence of the sense strand being shown in SEQ ID NO: 1, and the nucleotide sequence of the antisense strand being shown in SEQ ID NO:
2.
7. The pharmaceutical composition for combination therapy as described in claim 4, characterized in that, The immune checkpoint inhibitors include at least one of the following: anti-CTLA4 antibody, anti-PD1 antibody, anti-LAG3 antibody, anti-OX40 antibody, anti-TIM3 antibody, and anti-PDL1 antibody.
8. The pharmaceutical composition for combination therapy as described in claim 4, characterized in that, The PARP inhibitors include BMN673.
9. Use of a pharmaceutical composition as described in any one of claims 4-8 in the preparation of a medicament for treating tumors with low Cxcl9 expression.
10. The application as described in claim 9, characterized in that, The tumors include melanoma.
